Choice of psoriasis treatment affects CVD event rates

September 27, 2012
Choice of psoriasis treatment affects CVD event rates
Compared with other anti-psoriatic therapies, systemic anti-inflammatory treatment of patients with severe psoriasis with biologic agents or methotrexate is associated with a lower combined risk of death, myocardial infarction, and stroke, according to research published online Sept. 11 in the Journal of Internal Medicine.

(HealthDay)—Compared with other anti-psoriatic therapies, systemic anti-inflammatory treatment of patients with severe psoriasis with biologic agents or methotrexate is associated with a lower combined risk of death, myocardial infarction, and stroke, according to research published online Sept. 11 in the Journal of Internal Medicine.

Ole Ahlehoff, M.D., of the Copenhagen University Hospital in Gentofte, Denmark, and colleagues conducted a real-world study involving 2,400 Danish patients with severe psoriasis treated with systemic anti-inflammatory drugs, including 693 patients treated with and 799 treated with methotrexate, to measure cardiovascular disease event rates. The primary outcome was a composite end point of death, , and stroke.

The researchers found that, overall, 6.0, 17.3, and 44.5 events per 1,000 patient-years occurred in patients treated with biologic agents, methotrexate, and other therapies, respectively. Using the other psoriatic therapies (including retinoids, cyclosporine, and phototherapy) as a reference cohort, the risk of cardiovascular events was lower with biologic agents (hazard ratio [HR], 0.28) and methotrexate (HR, 0.65).

"In conclusion, in this nationwide study of patients with severe psoriasis, systemic anti-inflammatory treatment with biological agents or methotrexate was associated with reduced cardiovascular disease event rates," the authors write. "Further studies are needed to confirm these findings and evaluate their clinical implications."

Several authors disclosed to the pharmaceutical industry.

Explore further: Study examines risk of heart attack associated with various psoriasis treatments

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Study examines risk of heart attack associated with various psoriasis treatments

August 20, 2012
Use of tumor necrosis factor (TNF) inhibitors for treatment of psoriasis is associated with a significantly reduced risk for heart attack (myocardial infarction) compared to other forms of treatment, according to a report ...

Study compares effectiveness of psoriasis treatments

April 20, 2012
(HealthDay) -- The effectiveness of therapies for psoriasis is variable, and may be lower in real-world settings than in trial settings, according to a study published in the April issue of the Archives of Dermatology.

Treatment with anti-TNFs reduces the risk of cardiovascular events in rheumatoid arthritis

June 7, 2012
Results from a retrospective analysis of contemporary data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, predict, based on estimates from a multivariate regression model, that ...

Certain biologic therapies for psoriasis do not appear to increase risk for cardiovascular problems

August 23, 2011
Although some preliminary reports have indicated an increased risk of major adverse cardiovascular events with the use of certain biologic therapies to treat chronic plaque psoriasis, an analysis of previous studies finds ...

Common rheumatoid arthritis and psoriasis medications are associated with reduced diabetes risk

June 21, 2011
Individuals with systemic inflammatory conditions, such as rheumatoid arthritis (RA) and psoriasis, experience a 1.5 to 2-fold increased rate of cardiovascular disease. Previous research suggests that inflammation and insulin ...

Psoriasis patients face higher than average death risk after a heart attack

September 12, 2011
Heart attack patients with psoriasis are 26 per cent more likely to die from cardiovascular disease, or suffer from recurrent heart attacks or strokes, and are 18 per cent more likely to die from all causes than those without ...

Recommended for you

Improving vaccines for the elderly by blocking inflammation

January 22, 2018
By identifying why skin immunity declines in old age, a UCL-led research team has found that an anti-inflammatory pill could help make vaccines more effective for elderly people.

Novel genomic tools provide new insight into human immune system

January 19, 2018
When the body is under attack from pathogens, the immune system marshals a diverse collection of immune cells to work together in a tightly orchestrated process and defend the host against the intruders. For many decades, ...

First vaccine developed against grass pollen allergy

January 18, 2018
Around 400 million people worldwide suffer in some form or other from a grass pollen allergy (rhinitis), with the usual symptoms of runny nose, cough and severe breathing problems. In collaboration with the Viennese firm ...

Genomics reveals key macrophages' involvement in systemic sclerosis

January 18, 2018
A new international study has made an important discovery about the key role of macrophages, a type of immune cell, in systemic sclerosis (SSc), a chronic autoimmune disease which currently has no cure.

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.